🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

287 results for “Ono” Clear

  1. Traditional Chinese acupuncture

    The University of Hong Kong

    Phonotraumatic Injuries

    phase 2 other active

    1 trial

  2. Venetoclax monotherapy

    Adaptive Biotechnologies Corp

    Chronic Lymphocytic Leukemia (CLL)

    phase 2 small molecule active

    1 trial

  3. Vidaza 25 mg/ml powder for suspension for injection, Venclyxto 100 mg film-coated tablets, Venclyxto 10 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, Venclyxto 10 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, Venclyxto 100 mg film-coated tablets, Venclyxto 100 mg film-coated tablets

    Lacuna Pharma Pty Ltd

    Acute Myeloid Leukaemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML)

    phase 2 small molecule active

    1 trial

  4. Volrustomig

    AstraZeneca

    Sub-study 1 Cervical Cancer (Volrustomig Monotherapy)

    phase 2 mab active

    1 trial

  5. Vonoprazan

    Phathom Pharmaceuticals

    Eosinophilic Esophagitis

    phase 2 small molecule active

    1 trial

  6. Vonoprazan

    Takeda

    Gastroesophageal Reflux

    phase 2 small molecule completed

    1 trial

  7. cemiplimab (monotherapy)

    Regeneron UK Limited

    Relapsed Solid Tumor

    phase 2 small molecule terminated

    1 trial

  8. donor-derived NK cell infusion

    Chongqing Precision Biotech Co., Ltd

    Non-small Cell Lung Cancer

    phase 2 mab active

    1 trial

  9. long course radiotherapy + capecitabine + PD-1 monoclonal antibody treatment combinations

    BEONE MEDICINES AUS PTY LTD

    Colorectal Neoplasms

    phase 2 other active

    1 trial

  10. monoclonal factor IX replacement therapy

    Ultragenyx UK Limited

    Hemophilia B

    phase 2 small molecule completed

    1 trial

  11. nicotinamide adenine dinucleotid/nicotinamide mononucleotide

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Immune Thrombocytopenia

    phase 2 small molecule active

    1 trial

  12. recombinant humanized anti-CD25 monoclonal antibody

    The First People's Hospital of Lianyungang

    Transfusion Dependent Thalassemia

    phase 2 small molecule active

    1 trial

  13. silevertinib (BDTX-1535) monotherapy

    Blackmores Limited

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  14. "A study to test how well BI 3000202 is tolerated by people with type 1 interferonopathies"

    Boehringer Ingelheim

    Type 1 interferonopathies

    phase 1 other active

    1 trial

  15. 124I-labeled monoclonal antibody Mu 11-1F4

    BRIGHT MINDS BIOSCIENCES INC.

    AL Amyloidosis

    phase 1 mab completed

    1 trial

  16. A Clinical Study to Evaluate the Safety and Pharmacokinetics of JNJ- 73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung Cancer

    Janssen-Cilag International N.V.

    Advanced Non-Small Cell Lung Cancer

    phase 1 other active

    1 trial

  17. A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors

    TESARO Bio Netherlands B.V.

    Patients with Advanced Solid Tumors

    phase 1 other active

    1 trial

  18. A Phase 1 First-Time-in-Human, Open-Label Study of GSK4381562 Administered as Monotherapy and in Combination with Anticancer Agents in Participants with Selected Advanced Solid Tumors

    GlaxoSmithKline

    Neoplasms

    phase 1 other active

    1 trial

  19. A Phase 1 Open-label Study to Evaluate the Safety and Efficacy of MK‑8294 Monotherapy in Advanced Solid Tumors

    Merck Sharp and Dohme

    Breast Cancer, Cervical squamous cell carcinoma, Endometrial Carcinoma, Esophageal squamous cell carcinoma, Head and neck squamous cell carcinoma, Bladder Cancer

    phase 1 other active

    1 trial

  20. A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors (ARC-20)

    Arcus Biosciences

    Solid Tumors, Clear Cell Renal Cell Carcinoma

    phase 1 other active

    1 trial

  21. A Phase 1 Study of BMS-986406 as Monotherapy and in Combination in Advanced Tumors

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced Malignant Tumors

    phase 1 other active

    1 trial

  22. A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced or metastatic solid tumors, Gastroesophageal cancer (GEC), High grade serous ovarian cancer (HGSOC), Endometrial cancer (EC), Advanced or metastatic breast cancer, Platinum-resistant ovarian cancer (PROC)

    phase 1 other active

    1 trial

  23. A Phase 1 Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants with Severe, Refractory Autoimmune Diseases

    Bristol-Myers Squibb Australia Pty Ltd

    Systemic Sclerosis, Idiopathic Inflammatory Myopathy, Rheumatoid Arthritis, Systemic Lupus Erythematosus

    phase 1 other active

    1 trial

  24. A Phase 1 first in human study evaluating safety, pharmacokinetics and efficacy of ABBV-400 as monotherapy and in combination with bevacizumab in adult subjects with advanced solid tumors

    AbbVie Deutschland GmbH & Co. KG

    Advanced solid tumors including (but not limited to), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), gastric/gastroesophageal junction adenocarcinoma (GEA), colorectal cancer (CRC), and renal cell carcinoma (RCC)

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources